



Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from <https://aidsinfo.nih.gov/guidelines> on 8/31/2020

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <https://aidsinfo.nih.gov/e-news>.

What to Start: Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children (Last updated April 14, 2020; last reviewed April 14, 2020)

Panel's Recommendations

- The selection of an initial regimen should be individualized based on several factors, including the characteristics of the proposed regimen, the patient's characteristics, drug efficacy, potential adverse effects, patient and family preferences, and the results of viral resistance testing (AIII).
- For treatment-naive children, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommends initiating antiretroviral therapy with three drugs: a dual-nucleoside/nucleotide reverse transcriptase inhibitor backbone plus an integrase strand transfer inhibitor, a non-nucleoside reverse transcriptase inhibitor, or a boosted protease inhibitor (AI*).
- Table 7 provides a list of Panel-recommended regimens that are designated as *Preferred* or *Alternative*; recommendations vary by a patient's age, weight, and sexual maturity rating.

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

[†] Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents

Criteria Used for Recommendations

In general, the recommendations of the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) are based on reviews of pediatric and adult clinical trial data published in peer-reviewed journals, data prepared by manufacturers for Food and Drug Administration (FDA) review, and data presented in abstract format at major scientific meetings. Few randomized, Phase 3 clinical trials of antiretroviral therapy (ART) in pediatric patients have directly compared different treatment regimens. Most pediatric drug data come from Phase 1/2 safety and pharmacokinetic (PK) trials and nonrandomized, open-label studies. In general, even in studies of adults, assessment of drug efficacy and potency is primarily based on surrogate marker endpoints, such as CD4 T lymphocyte (CD4) cell count and viral load. The Panel continually modifies recommendations on optimal initial therapy for children as new data become available, new therapies or drug formulations are developed, and additional toxicities are recognized.

When developing recommendations for specific drugs or regimens, the Panel considers the following information:

- Data demonstrating durable viral suppression, immunologic improvement, and clinical improvement (when available) with the drug or regimen, preferably in children as well as adults;
- The extent of pediatric experience with a specific drug or regimen;
- The incidence and types of short-term and long-term drug toxicity in people who are taking the drug or regimen, focusing on toxicities that are reported in children;
- The availability and acceptability of formulations that are appropriate for pediatric use, including palatability, ease of preparation (e.g., syrups vs. powders), pill size, and the number of pills or volume of oral solution needed for an appropriate dose;
- Dosing frequency and food and fluid requirements; *and*
- The potential for drug interactions with other medications.

The Panel classifies recommended drugs or drug combinations into one of two categories:

- *Preferred*: Drugs or drug combinations are designated as *Preferred* for use in treatment-naïve children when clinical trial data in children or, more often, in adults have demonstrated optimal and durable efficacy with acceptable toxicity and ease of use, and pediatric studies using surrogate markers have demonstrated safety and appropriate drug exposure. Additional considerations are listed above.
- *Alternative*: Drugs or drug combinations are designated as *Alternative* for initial therapy when clinical trial data in children or adults show efficacy, but the drugs or drug combinations have disadvantages when compared with *Preferred* regimens. Drugs or drug combinations may be classified as *Alternative* for use in treatment-naïve children if they are less effective or durable than a *Preferred* regimen in adults or children; if there are specific toxicity, dosing, formulation, administration, or interaction concerns; or if there is limited experience with the use of these drugs or drug combinations in children.

Factors to Consider When Selecting an Initial Regimen

An antiretroviral (ARV) regimen for children should generally consist of two nucleoside reverse transcriptase inhibitors (NRTIs) plus an active drug from one of the following classes: an integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a boosted protease inhibitor (PI). Choice of a regimen should be individualized based on several factors, including the characteristics of the proposed regimen; the patient's age, weight, sexual maturity rating (SMR), and other characteristics; and the results of drug-resistance testing.

Drug recommendations often include both age and weight limitations. Although age can be used as a rough guide, body weight (when available) is the preferred determinant for selecting a specific drug. An exception to this is infants aged <14 days. Many drugs that are recommended for use in very young infants do not have dosing recommendations for premature infants. Additional information regarding dosing recommendations in this population can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#).

The advantages and disadvantages of each regimen are described in detail in the sections that follow and in Table 8. Additional information regarding the advantages and disadvantages of specific drug combinations can be found in the [What to Start](#) section of the [Adult and Adolescent Antiretroviral Guidelines](#). Specific information about the clinical efficacy, adverse events (AEs), and dosing recommendations for each drug can be found in [Appendix A: Pediatric Antiretroviral Drug Information](#). In addition, clinicians should consider potential barriers to adherence. These barriers may include complex dosing schedules, food requirements, the need to use multiple formulations to achieve an appropriate dose, and palatability problems. Counseling patients and caregivers about adherence to therapy **is essential for successful ART. The Panel recommends rapid initiation of ART (defined as initiating ART immediately or within days of diagnosis).**

Emtricitabine (FTC), lamivudine (3TC), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) have antiviral activity and efficacy against hepatitis B virus (HBV) and should be considered for use in children with HBV/HIV coinfection. For a comprehensive [review of this topic](#), as well as a review of [hepatitis C](#) and [tuberculosis](#) in patients with HIV, see the [Pediatric Opportunistic Infection Guidelines](#).

Choosing an Initial Antiretroviral Regimen for Children with HIV

Preferred regimens for initial therapy include INSTI-based, NNRTI-based, or boosted PI-based regimens. A regimen should be chosen after considering the patient's individual characteristics (especially age), the results of drug-resistance testing, potential AEs, pill size, and dosing frequency. Adherence to a prescribed regimen is necessary; therefore, the preferences of the patient and caregivers should also be considered when choosing a regimen.

Clinical trial data in children provide some guidance for choosing between an NNRTI-based regimen and a PI-based regimen for initial therapy. Three pediatric studies have compared an NNRTI-based regimen to

a PI-based regimen, and results varied based on the age of the population studied and the specific drug used within the class.

- The P1060 study demonstrated the superiority of a lopinavir/ritonavir (LPV/r)-based regimen over a nevirapine (NVP)-based regimen in infants and children aged 2 to 35 months, regardless of maternal or infant exposure to peripartum, single-dose NVP prophylaxis. In children with prior NVP exposure, 21.7% of children receiving the LPV/r-based regimen experienced death, virologic failure, or toxicity by Week 24 compared to 39.6% of children receiving the NVP-based regimen. For children with no prior NVP exposure, death, virologic failure, and toxicity occurred in 18.4% of children receiving the LPV/r-based regimen and 40.1% of children receiving the NVP-based regimen.¹
- Those in the NVP group demonstrated greater, but not statistically significant, improvements in CD4 counts and growth parameters. However, improvements in CD4 counts were only maintained up to 1 year after initiation of ART.² Similar improved immune and growth parameters were reported in the NEVEREST study, where these parameters were compared in children who switched to a NVP-containing regimen and those who continued on a LPV/r-containing regimen after achieving virologic suppression.³ Improvements in metabolic parameters have also been seen in children who switched from LPV/r to efavirenz (EFV) at or after 3 years of age.⁴
- PENPACT-1 (PENTA 9/PACTG 390) compared a PI-based regimen and a NNRTI-based regimen in treatment-naïve children aged 30 days to <18 years (the study did not dictate the use of specific NNRTIs or PIs). In the PI-based regimen group, 49% of children received LPV/r and 48% received nelfinavir; in the NNRTI-based regimen group, 61% of children received EFV and 38% received NVP. After 4 years of follow-up, 73% of children who were randomized to receive PI-based therapy and 70% who were randomized to receive NNRTI-based therapy remained on their initial ARV regimen. In both groups, 82% of children had viral loads <400 copies/mL.⁵
- The PROMOTE-pediatrics trial demonstrated comparable virologic efficacy among children who were randomized to receive either an NNRTI-based or a LPV/r-based ARV regimen.⁶ Children were aged 2 months to <6 years and had no perinatal exposure to NVP. Selection of the NNRTI was based on age (children aged <3 years received NVP, and those aged >3 years primarily received EFV). The proportion of children with viral loads <400 copies/mL at 48 weeks was 80% in the LPV/r arm versus 76% in the NNRTI arm, a difference of 4% that was not statistically significant (95% confidence interval [CI], -9% to +17%).

Clinical investigation of INSTI-based regimens in children has been limited to noncomparative studies that have evaluated the safety, tolerability, and PKs of these drugs. The recommendation for using an INSTI as part of an initial regimen is based largely on extrapolation from adult comparative trials that showed that INSTI-containing regimens have superior efficacy when compared to PI-containing and NNRTI-containing regimens^{7,8} and small studies in ART-naïve adolescents.⁹

When combined with two NRTIs, the following drugs and drug combinations are considered *Preferred* regimens for children:

- Children aged <14 days: NVP
- Children aged <14 days and weighing ≥ 2 kg: Raltegravir (RAL)
- Children aged ≥ 14 days to <3 years: LPV/r or RAL
- Children aged ≥ 3 years and
 - Weighing <25 kg: Atazanavir/ritonavir (ATV/r), twice-daily darunavir/ritonavir (DRV/r), or RAL
 - Weighing ≥ 25 kg: Dolutegravir (DTG)
 - Weighing ≥ 25 kg: Elvitegravir/cobicistat (EVG/c). Only the fixed-dose combination (FDC) tablet that contains elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/c/FTC/TAF) is recommended at this time.

- Adolescents aged ≥ 12 years and weighing ≥ 25 kg: Bictegravir (BIC). BIC is only available as a component of the FDC tablet bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).

Alternative regimens are shown in Table 7 below.

Integrase Strand Transfer Inhibitor-Based Regimens

Four INSTIs—BIC, DTG, EVG, and RAL—are approved by the FDA for treating ARV-naïve adults and children with HIV. INSTI-based regimens have quickly become the recommended regimens in adults because of their virologic efficacy, lack of drug interactions, and favorable toxicity profile. RAL is approved for the treatment of infants and children from birth onwards with weights of ≥ 2 kg. DTG is approved by the FDA for use in children weighing ≥ 30 kg. The FDC tablet BIC/FTC/TAF (Biktarvy) is approved by the FDA for use in children weighing ≥ 25 kg. EVG has been studied in adolescents in two FDC regimens and in combination with two NRTIs and ritonavir (RTV) boosting. BIC and DTG, the second-generation INSTIs, have higher barriers to resistance than the first-generation INSTIs RAL and EVG^{10,11} and may have more activity against non-B subtypes of HIV.^{12,13}

Table 8 lists the advantages and disadvantages of using INSTIs. See [Appendix A: Pediatric Antiretroviral Drug Information](#) for detailed pediatric information on each drug.

Bictegravir

BIC is available only as part of an FDC tablet that contains BIC 50 mg/FTC 200 mg/TAF 25 mg and is marketed as Biktarvy. BIC/FTC/TAF was approved by the FDA in 2018 for use in adults and in 2019 for use in children or adolescents weighing ≥ 25 kg. Biktarvy is approved for use in patients who have no ARV treatment history, and it can also be used to replace the current ARV regimen in patients who have been virologically suppressed (viral load < 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of the FDC tablet.

Biktarvy was administered to adolescents aged 12 years to < 18 years and weighing ≥ 35 kg who had maintained viral loads < 50 copies/mL for ≥ 6 months. The drug was well tolerated; all 24 participants in the study had viral loads < 50 copies/mL at Week 24, and drug exposure in these adolescent patients was similar to the exposure observed in adults. Another study demonstrated the efficacy and tolerability of Biktarvy in children aged 6 years to < 12 years who weighed ≥ 25 kg, although serum trough concentrations were more variable in this child cohort than in adolescent or adult cohorts.^{14,15}

The two studies described above were combined and continued for 48 weeks, at which time 74 of 75 participants had viral loads < 50 copies/mL.¹⁴

Recommendation:

- BIC/FTC/TAF is recommended as a *Preferred* INSTI-based regimen for adolescents aged ≥ 12 years and weighing ≥ 25 kg (**AI***) and as an *Alternative* INSTI-based regimen for children aged ≥ 6 years and weighing ≥ 25 kg (**AI***). The Panel bases this recommendation on the virologic potency and safety profile observed for this combination in adult and pediatric studies.

Dolutegravir

The FDA has approved DTG for use in children weighing ≥ 30 kg. The approval was supported by data from a study of 46 treatment-experienced (but INSTI-naïve) adolescents^{9,16} and 11 treatment-experienced (but INSTI-naïve) children aged ≥ 6 years.¹⁷ The World Health Organization (WHO) recommends using DTG in children weighing ≥ 20 kg. This recommendation is based on PK and safety data from two ongoing clinical trials (IMPACT P1093 and ODYSSEY). The Panel agrees with the WHO assessment that DTG can be used in children weighing ≥ 20 kg (see the [Dolutegravir](#) section in [Appendix A: Pediatric Antiretroviral Drug Information](#));¹⁸ DTG has a very favorable safety profile and can be given once daily to treat INSTI-naïve patients. Studies of DTG are ongoing in children as young as 4 weeks of age.¹⁹

In a prospective surveillance study of birth outcomes among pregnant women on ART in Botswana, a small but significant increase in the risk of neural tube defects (NTDs) was observed among infants born to women who were receiving DTG at the time of conception.²⁰⁻²² Specific recommendations about the initiation and use of DTG in adults and adolescents of childbearing potential and in those who are pregnant or trying to conceive are available in the Adult and Adolescent Antiretroviral Guidelines (see [Table 6b](#) and [Adolescents and Young Adults with HIV](#)) and in the Perinatal Guidelines (see [Teratogenicity](#), [Recommendations for Use of Antiretroviral Drugs During Pregnancy](#), and [Appendix D: Dolutegravir Counseling Guide for Health Care Providers](#)).

Recommendation:

- DTG plus a two-NRTI backbone is recommended as a *Preferred* INSTI-based regimen for children and adolescents aged ≥ 3 years and weighing ≥ 25 kg (AI*). The Panel bases this recommendation on the virologic potency and safety profile observed for this combination in adult and pediatric studies.^{7,9,23,24}
- DTG plus a two-NRTI backbone is recommended as an *Alternative* INSTI-based regimen for children aged ≥ 3 years and weighing ≥ 20 kg to < 25 kg (AI*). Data are limited on the efficacy and safety of using DTG in this weight group, and DTG PKs vary more among children in this weight group than among those weighing ≥ 25 kg.
- In light of concerns about the potential increased risk of NTDs with the use of DTG, pediatric and adolescent care providers should discuss this risk with patients who are receiving or initiating DTG and their caregivers so they can make informed decisions about the use of DTG (see [Appendix D: Dolutegravir Counseling Guide for Health Care Providers](#) in the [Perinatal Guidelines](#)). Specific recommendations about the use of DTG in women of childbearing potential, pregnant women, and women who are trying to conceive are available in the [Adult and Adolescent Antiretroviral Guidelines](#) (see [Table 6b](#)) and in the [Perinatal Guidelines](#) (see [Teratogenicity](#) and [Recommendations for Use of Antiretroviral Drugs During Pregnancy](#)).

Elvitegravir

EVG is an INSTI that is available as a single-drug tablet, an FDC tablet that contains EVG/c/FTC/TDF, and an FDC tablet that contains EVG/c/FTC/TAF. Both FDC tablets are approved by the FDA for use in ART-naïve adults with HIV. EVG/c/FTC/TAF is approved for use in ART-naïve children and adolescents weighing ≥ 25 kg. Cobicistat (COBI) is a specific, potent cytochrome P450 (CYP) 3A inhibitor that has no activity against HIV. It is used as a PK enhancer, which allows for once-daily dosing of EVG.

Recommendation:

- EVG/c/FTC/TAF is recommended as a *Preferred* INSTI-based regimen for children and adolescents weighing ≥ 25 kg who have creatinine clearance (CrCl) ≥ 30 mL/min (AI*). The Panel bases this recommendation on the virologic potency and safety profile observed for this combination in adult and adolescent studies.²⁵⁻³⁰

Raltegravir

RAL is approved by the FDA for treatment of infants and children weighing ≥ 2 kg, and it can be used starting at birth. It is available in film-coated tablets, chewable tablets, and single-use packets of granules for oral suspension. Clinicians should consult with an expert in pediatric HIV infection when initiating RAL-based treatment regimens in neonates, infants, and very young children. Additional information can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#).

Recommendation:

- RAL plus a two-NRTI backbone is recommended as a *Preferred* INSTI-based regimen for infants and children from birth to age 3 years who weigh ≥ 2 kg and for children aged ≥ 3 years and weighing < 25 kg.

(AI*). It is an *Alternative* INSTI-based regimen for children aged ≥ 3 years and weighing ≥ 25 kg (AI*). The Panel bases this recommendation on data from randomized clinical trials in adults and pediatric studies that were performed largely in ARV-experienced children and adolescents.^{7,31-38} The Panel acknowledges that data regarding the efficacy of this agent in those aged < 2 years are currently very limited.³⁹

- At this time, the Panel **does not recommend** once-daily dosing of RAL for initial therapy in children and infants.

Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens

EFV (for children aged ≥ 3 months), etravirine (ETR; for children aged ≥ 6 years), NVP (for children aged ≥ 15 days), and rilpivirine (RPV; for children aged ≥ 12 years) have been approved by the FDA for treatment of HIV infection in pediatric patients. NNRTIs have a long half-life that allows for less-frequent drug administration, a lower risk of dyslipidemia and fat maldistribution than some agents in the PI class, and, generally, a lower pill burden than PIs. However, a single viral mutation can confer high-level drug resistance to all NNRTIs except ETR, and cross-resistance to other NNRTIs is common. Rare, but serious and potentially life-threatening, skin and hepatic toxicity can occur with the use of all NNRTI drugs, but these AEs are most frequently observed in patients taking NVP, at least among adults with HIV. NNRTIs have the potential to interact with other drugs that are also metabolized via hepatic enzymes; however, these drug interactions are less frequent with NNRTIs than with boosted-PI regimens. [Table 8](#) lists the advantages and disadvantages of using NNRTIs. See [Appendix A: Pediatric Antiretroviral Drug Information](#) for detailed pediatric information for each drug.

Efavirenz

Although EFV dosing recommendations are available for patients aged ≥ 3 months and weighing ≥ 3.5 kg, the Panel does not endorse the use of this drug in infants and children aged 3 months to 3 years because the PKs of EFV in very young patients can be highly variable.

Recommendation:

- EFV plus a two-NRTI backbone is recommended as an *Alternative* NNRTI-based regimen for initial treatment of HIV in children aged ≥ 3 years (AI*). The Panel bases this recommendation on data from studies that evaluated the efficacy and tolerability of this drug in adults and children.^{23,31,40-58}

Nevirapine

There are extensive clinical and safety data for the use of NVP in children with HIV, and NVP has shown ARV efficacy when used as a component in a variety of combination regimens.^{1,5,6,59-63} NVP has also been used extensively as prophylaxis for the prevention of HIV transmission in young infants during the peripartum period and during breastfeeding. The safety and PKs of NVP have been studied at the low doses of the drug that are used for prophylaxis. There is currently less information available from studies in very young infants about the safety and PKs of the higher NVP doses that are necessary for treatment.

Early testing of infants allows HIV infection to be confirmed before 14 days of age. The Panel recommends the use of NVP as a *Preferred* NNRTI when a clinician plans to initiate treatment prior to age 14 days. However, there are currently no clinical trial data suggesting that initiating treatment within the first 14 days of life improves outcomes compared to starting after age 14 days. Clinicians should consult an expert in pediatric HIV infection when considering the use of NVP in infants aged < 14 days. Additional considerations regarding the use of NVP in infants aged < 14 days can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#).

Recommendation:

- NVP plus a two-NRTI backbone is recommended as a *Preferred* NNRTI-based regimen in infants

aged <14 days and an *Alternative* NNRTI-based regimen for children aged ≥ 14 days to <3 years (**AI**). Clinicians should consider switching from NVP to LPV/r or RAL in children aged ≥ 14 days to <3 years, as these drugs are the *Preferred* ARV agents for this age bracket. LPV/r has better clinical outcomes than NVP in children aged <3 years. The Panel recommends switching from NVP to LPV/r in these patients, because NVP is associated with rare occurrences of significant hypersensitivity reactions (HSRs), including Stevens-Johnson syndrome, and rare (but potentially life-threatening) instances of hepatitis. NVP also has a low barrier to resistance, and there is conflicting data about the virologic efficacy of NVP-based regimens compared to the efficacy of *Preferred* regimens.^{1,5,6,61-73}

Rilpivirine

RPV is currently available both as a single-drug tablet and a once-daily FDC tablet that contains FTC/RPV/TDF. The single-drug tablet is approved for use in children and adolescents aged ≥ 12 years.

Recommendation:

- RPV plus a two-NRTI backbone is recommended as an *Alternative* NNRTI-based regimen for children and adolescents aged ≥ 12 years and weighing ≥ 35 kg who have HIV viral loads $\leq 100,000$ copies/mL (**AI***). The Panel bases this recommendation on the limited experience with RPV in adolescents and the larger body of evidence in adults.^{47,74-78}

Protease Inhibitor-Based Regimens

Advantages of PI-based regimens include excellent virologic potency and a high barrier to drug resistance (since multiple mutations are required for a patient to develop resistance). However, because PIs are metabolized via hepatic enzymes, these drugs have the potential for multiple drug interactions. They may also be associated with metabolic complications such as dyslipidemia, fat maldistribution, and insulin resistance. Factors to consider when selecting a PI-based regimen for treatment-naïve children include virologic potency, dosing frequency, pill burden, food or fluid requirements, the availability of palatable pediatric formulations, the drug interaction profile, the toxicity profile (particularly toxicities related to metabolic complications), the age of the child, and the availability of data regarding the use of the drug in children. [Table 8](#) lists the advantages and disadvantages of using PIs. See [Appendix A: Pediatric Antiretroviral Drug Information](#) for detailed pediatric information on each drug.

RTV is a potent inhibitor of the CYP3A4 isoenzyme and can be used in low doses as a PK booster when coadministered with some PIs, increasing drug exposure by prolonging the half-life of the boosted PI. Currently, only LPV/r is available as a coformulated product. In addition, the use of RTV boosting increases the risk of hyperlipidemia⁷⁹ and drug interactions. **COBI is an alternative CYP3A4 inhibitor that can also be used as a booster. It is available in a single-drug tablet and in coformulations with ATV and with DRV. Currently, the single-drug tablet is approved by the FDA for administration with ATV in children weighing ≥ 35 kg and for administration with DRV in children weighing ≥ 40 kg.**

Preferred and *Alternative* PIs are presented in **alphabetical** order below.

Atazanavir Boosted with Ritonavir or Cobicistat

ATV is a once-daily PI that was approved by the FDA in March 2008 for use in combination with a two-NRTI backbone in children aged ≥ 6 years. ATV is most often boosted with RTV. Approval was extended in 2014 for use in infants and children aged ≥ 3 months and weighing ≥ 5 kg.^{80,81} **ATV administered in combination with COBI has been approved by the FDA for use in adults and, using the single-agent COBI tablet, in children weighing ≥ 35 kg.**

Recommendation:

- ATV/r plus a two-NRTI backbone is recommended as a *Preferred* PI-based regimen for children aged ≥ 3 years and weighing <25 kg. It is an *Alternative* PI-based regimen for children aged ≥ 3 months to <3

years and children aged ≥ 3 years and weighing ≥ 25 kg (**AI***). Atazanavir/cobicistat plus a two-NRTI backbone is an *Alternative* PI-based regimen for children weighing ≥ 35 kg. These regimens have been shown to be virologically potent in adult and pediatric studies and have been well tolerated in pediatric studies. However, the oral powder formulations of ATV and RTV and the oral solution formulation of RTV can be cumbersome to administer.^{34,43,76,79,82-88}

- The Panel **does not recommend** the use of unboosted ATV.

Darunavir Boosted with Ritonavir or Cobicistat

DRV/r is approved by the FDA for use in ARV-naïve and ARV-experienced children aged ≥ 3 years and weighing ≥ 10 kg. In addition, once-daily dosing of DRV/r is approved for ARV-naïve children aged ≥ 3 years and weighing ≥ 10 kg, and for ARV-experienced patients who do not have DRV resistance-associated mutations. Once-daily dosing of DRV/r was investigated during a substudy of a twice-daily dosing trial in children aged 3 years to <12 years. This PK evaluation lasted only 2 weeks, after which the participants switched back to the twice-daily regimen.⁸⁹ FDA dosing recommendations are based on PK models from this study, but this dose has never undergone trials for clinical efficacy in this age group. A more recent study also suggested that once-daily DRV/r dosing is acceptable for children and adolescents. In this study, the plasma concentration-time curve for DRV/r was substantially lower than the mean value observed in adults; however, trough levels were similar. Because of these findings, and due to the lack of more information about the efficacy of once-daily DRV/r dosing in ARV-naïve and ARV-experienced children aged <12 years, the Panel recommends a twice-daily dose of DRV/r in children aged >3 years to <12 years.⁹⁰ DRV administered in combination with COBI has been approved by the FDA for use in adults and, using the single-agent COBI tablet, in children weighing ≥ 40 kg.⁹¹

Recommendation:

- DRV/r plus a two-NRTI backbone is recommended as a *Preferred* PI-based regimen for children aged ≥ 3 years and weighing ≥ 10 kg but <25 kg, and as an *Alternative* PI-based regimen for children aged ≥ 3 years and weighing ≥ 25 kg (**AI***). The Panel bases these recommendations on the virologic potency shown by DRV/r in adult and pediatric studies, and this combination's high barrier to the development of drug resistance and excellent toxicity profile in adults and children.^{34,90,92-98}
- Based on findings from the DIONE study, once-daily dosing of DRV/r is part of an *Alternative* PI-based regimen in ARV-naïve children and adolescents weighing ≥ 40 kg (**AI***).
- Twice-daily dosing of DRV/r should be used for children aged ≥ 3 years to <12 years.
- Twice-daily dosing of DRV/r should be used when the following DRV resistance-associated substitutions are present in the HIV protease: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V.
- DRV/c plus a two-NRTI backbone is recommended as an *Alternative* PI-based regimen for adolescents aged ≥ 12 years and weighing ≥ 40 kg who are not sexually mature.

Lopinavir/Ritonavir

LPV/r is approved to treat HIV infection in infants and children with a postmenstrual age ≥ 42 weeks and postnatal age ≥ 14 days. Once-daily LPV/r dosing is approved by the FDA for initial therapy in adults,⁹⁹ but PK data in children do not support a recommendation for once-daily dosing.¹⁰⁰⁻¹⁰²

Recommendation:

- LPV/r plus a two-NRTI backbone is recommended as a *Preferred* PI-based regimen for infants with a postmenstrual age ≥ 42 weeks and postnatal age ≥ 14 days to <3 years (**AI**) and as an *Alternative* PI-based regimen in children aged ≥ 3 years (**AI***). This regimen has been shown to be virologically potent in adult and pediatric studies and has been well tolerated in pediatric studies.^{23,45,82,83,92,99-101,103-107}

Selection of Dual-Nucleoside Reverse Transcriptase Inhibitor Backbone as Part of Initial Combination Therapy

Dual-NRTI combinations form the backbone of combination regimens for both adults and children. Currently, eight NRTIs (zidovudine [ZDV], didanosine [ddI], 3TC, stavudine [d4T], abacavir [ABC], FTC, TDF, and TAF) are approved by the FDA for use in children aged <13 years. Dual-NRTI combinations that have been studied in children include:

- ZDV used in combination with ABC, ddI, or 3TC
- ABC used in combination with 3TC, d4T, or ddI
- FTC used in combination with d4T or ddI
- TDF used in combination with 3TC or FTC
- TAF used in combination with FTC^{29,53,84,108-112}

The Panel **no longer recommends** using ddI or d4T as part of ARV regimens for children due to the significant toxicities observed when using these drugs and the availability of safer agents. The advantages and disadvantages of the different dual-NRTI backbone options that are recommended for initial therapy in children are listed in [Table 8](#). See [What Not to Start](#) for more information. Also, see [Appendix A: Pediatric Antiretroviral Drug Information](#) for detailed pediatric information on each drug.

In the dual-NRTI backbones listed below, 3TC and FTC are interchangeable. Both 3TC and FTC are well tolerated and have few AEs. FTC is similar to 3TC and can be substituted for 3TC as one component of a preferred dual-NRTI backbone (i.e., FTC used in combination with ABC, TDF, or ZDV). The main advantage of FTC over 3TC is that it can be administered once-daily as part of an initial regimen. Both 3TC and FTC select for the M184V resistance mutation, which is associated with high-level resistance to both drugs, a modest decrease in susceptibility to ABC, and improved susceptibility to ZDV and TDF as a result of decreased viral fitness.^{113,114}

Dual-Nucleoside Reverse Transcriptase Inhibitor Backbones

Dual-NRTI combinations are presented in **alphabetical** order below.

Abacavir in Combination with Lamivudine or Emtricitabine

ABC is approved for use in children aged ≥3 months when administered as part of an ARV regimen.

Recommendation:

- ABC plus 3TC or FTC is recommended as the *Preferred* dual-NRTI combination for children aged ≥3 months (**AI**). Studies of adults and children have reported virologic efficacy and favorable toxicity profiles for these combinations.^{32,115-122}
- Once-daily dosing is recommended when using the pill formulation of ABC. Twice-daily dosing of liquid ABC is recommended for initial therapy; a change to once-daily dosing can be considered for clinically stable patients with undetectable viral loads and stable CD4 counts.¹²³⁻¹²⁶

Tenofovir Alafenamide in Combination with Emtricitabine

TAF is an oral prodrug of tenofovir. It is approved by the FDA as a component of an FDC tablet that also contains EVG, COBI, and FTC for the treatment of HIV in ARV-naïve individuals weighing ≥25 kg who have an estimated CrCl ≥30 mL/min. Additional safety and PK data are available for children aged 6 years to <12 years who are receiving this FDC tablet.³⁰ An FDC tablet that contains FTC/TAF (Descovy) is also available.

Recommendation:

- FTC/TAF is recommended as a *Preferred* dual-NRTI combination in children and adolescents weighing ≥ 25 kg who have estimated CrCl ≥ 30 mL/min when this combination is used with an INSTI or NNRTI; this combination is considered a *Preferred* dual-NRTI combination when used with a PI in children and adolescents weighing ≥ 35 kg who have estimated CrCl ≥ 30 mL/min (**AI***). This combination is also recommended as a *Preferred* drug combination when used in the single-tablet regimen EVG/c/FTC/TAF for children and adolescents weighing ≥ 25 kg (**AI***). The Panel makes these recommendations because TAF has a lower risk of renal and bone AEs than TDF.^{27,127}
- FTC/TAF is neither approved by the FDA nor recommended for use in combination with a boosted PI in children weighing < 35 kg, because this combination has not been adequately studied in this age and weight group.

Tenofovir Disoproxil Fumarate in Combination with Lamivudine or Emtricitabine

TDF is approved by the FDA for use in children and adolescents aged ≥ 2 years when administered as part of an ARV regimen. Decreases in bone mineral density (BMD) have been observed in adults and children receiving TDF, but the clinical significance of these decreases is unknown.^{109-112,128,129} Before starting treatment, clinicians should consider whether the benefits of using TDF outweigh the potential risks of decreased BMD.¹³⁰

Recommendation:

- TDF plus 3TC or FTC is recommended as an *Alternative* dual-NRTI combination for children aged ≥ 2 years to 12 years (**AI***). The Panel bases this recommendation on the virologic efficacy and ease of dosing of these combinations.^{109-112,116-119,131-136}

Zidovudine in Combination with Abacavir

In a European pediatric study, patients who received ZDV plus ABC had lower rates of viral suppression and a greater number of toxicities that lead to regimen modification than patients who received ABC plus 3TC.^{108,115}

Recommendation:

- ZDV plus ABC is recommended as an *Alternative* dual-NRTI combination for children aged ≥ 3 months (**BII**).

Zidovudine in Combination with Lamivudine or Emtricitabine

ZDV is available as a syrup, a capsule, and a tablet, and it is also available in injectable/intravenous preparations. It is approved by the FDA for treatment of HIV in infants aged ≥ 4 weeks and for prophylaxis in newborns.

Recommendation:

- ZDV plus 3TC or FTC is recommended as a *Preferred* dual-NRTI combination for infants and children from birth to age ≤ 6 years, and an *Alternative* combination in children aged ≥ 6 years and adolescents (**AI***). However, twice-daily dosing is required for ZDV in children aged ≥ 6 years. Other NRTIs that only require once-daily dosing in children aged ≥ 6 years are available.^{120,137-139}
- ZDV plus ABC is recommended as an *Alternative* dual-NRTI combination for use in children aged ≥ 3 months (**BII**). In children aged ≥ 6 years and adolescents who are not sexually mature (i.e., those with SMRs of 1–3), the Panel recommends ZDV plus 3TC or FTC as an *Alternative* dual-NRTI combination (**BII**).

Figure 1. Preferred Regimen by Age, Weight and Drug Class

		Patient Age and Weight Class				
		Birth to <14 Days of Age ^{a,b,c}	Children Aged ≥14 Days to <3 Years	Children Aged ≥3 Years <u>and</u> Weighing <25 kg	Children Aged ≥3 Years <u>and</u> Weighing ≥25 kg	Adolescents Aged ≥12 Years <u>and</u> Weighing ≥25 kg
INSTI-Based Regimens		Two NRTIs plus RAL ^c				
					Two NRTIs plus BIC ^d	
					Two NRTIs plus DTG ^e	
					Two NRTIs plus EVG/COBI ^f	
NNRTI-Based Regimens		Two NRTIs plus NVP ^{a,g}				
PI-Based Regimens		Two NRTIs plus LPV/r ^b				
				Two NRTIs plus ATV/r		
				Two NRTIs plus DRV/r ^h		

^a If treatment is scheduled to begin before a patient is aged 14 days, NVP or RAL are *Preferred* agents because they are the only options with dosing information available for this age group. While many pediatric experts favor initiating ART as soon as possible after birth in order to limit the establishment of viral reservoirs, available clinical trial data does not suggest that initiating treatment within the first 14 days of life leads to better clinical outcomes than initiating treatment after 14 days of age. Clinicians should consult an expert in pediatric HIV infection before initiating treatment in infants aged <14 days. Additional considerations regarding the use of NVP or RAL in infants aged <14 days can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#). Switching from NVP to LPV/r should be considered when the infant is aged ≥14 days with a postmenstrual age of 42 weeks (the span of time between the first day of the mother's last menstrual period and birth, plus the time elapsed after birth); LPV/r has produced better clinical outcomes in studies of children aged <3 years than NVP. Data are limited on the clinical outcomes of using RAL in infants and children aged <2 years.

^b In general, LPV/r **should not be administered** to neonates before a postmenstrual age of 42 weeks and a postnatal age of ≥14 days (see the [Lopinavir/Ritonavir](#) section in [Appendix A: Pediatric Antiretroviral Drug Information](#)).

^c RAL can be used in infants weighing ≥2 kg. RAL pills or chewable tablets can be used in children aged ≥2 years. Granules can be administered to infants and children from birth to age 2 years.

^d BIC is available only as part of an FDC tablet that contains BIC/FTC/TAF; this FDC tablet is recommended as a *Preferred* regimen for adolescents aged ≥12 years and weighing ≥25 kg. It is recommended as an *Alternative* regimen for children aged ≥6 years and weighing ≥25 kg.

^e DTG is recommended as a *Preferred* agent only for children and adolescents aged ≥3 years and weighing ≥25 kg. It is recommended as an *Alternative* agent in children aged ≥3 years and weighing 20 kg to <25 kg. For children weighing <20 kg, the use of RAL can be considered when an INSTI-based regimen is desired.

^f EVG is currently recommended only as a component of FDC tablets. Tablets containing EVG/c/FTC/TAF are recommended as a *Preferred* regimen for children and adolescents weighing ≥25 kg.

^g NVP should not be used in post-pubertal girls with CD4 counts >250/mm³, unless the benefit clearly outweighs the risk. NVP is approved by the FDA for the treatment of infants aged ≥15 days.

^h Once-daily DRV should not be used in children aged <12 years or weighing <40 kg. Once-daily DRV should also not be used when any one of the following resistance-associated substitutions are present: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V. DRV/r is recommended as an *Alternative* drug combination for children aged ≥6 years to <12 years, because there are other drugs that can be administered once daily. This combination is considered a *Preferred* option for adolescents aged ≥12 years with SMRs of 1–3 when once-daily administration is possible.

Key: ART = antiretroviral therapy; ATV/r = atazanavir/ritonavir; BIC = bictegravir; CD4 = CD4 T lymphocyte; COBI = cobicistat; DRV = darunavir; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDA = Food and Drug Administration; FDC = fixed-dose combination; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; SMR = sexual maturity rating; TAF = tenofovir alafenamide

Table 7. Antiretroviral Regimens Recommended for Initial Therapy for HIV Infection in Children

An ARV regimen for treatment-naïve children is generally made up of a two-NRTI backbone and either one NNRTI or one INSTI or one PI boosted with RTV or COBI. Regimens are designated *Preferred* based on efficacy, ease of administration, and acceptable toxicity. *Alternative* regimens have also demonstrated efficacy, but clinical experience with these regimens is limited or these regimens are more difficult to administer than *Preferred* regimens. Regimens should be tailored to the individual patient by weighing the advantages and disadvantages of each combination. Many agents have multiple formulations and age and weight recommendations. Please consult [Appendix A: Pediatric Antiretroviral Drug Information](#) for additional information and recommended doses and formulations (see [Table 8](#) below).

Children who are receiving effective and tolerable ARV regimens can continue using those regimens as they age, even if the combinations they are receiving are no longer *Preferred* regimens.

Preferred Regimens			
Age	Regimens		FDC Available (see Appendix A, Table 1)
Infants, Birth to Age <14 Days ^{a,b}	Two NRTIs plus NVP		No
	Weight ≥2 kg	Two NRTIs plus RAL ^c	No
Children Aged ≥14 Days to <3 Years	Two NRTIs plus LPV/r ^b		No
	Weight ≥2 kg	Two NRTIs plus RAL ^c	No
Children Aged ≥3 Years	Weight <25 kg	Two NRTIs plus ATV/r	No
		Two NRTIs plus twice-daily DRV/r ^d	No
		Two NRTIs plus RAL ^c	No
	Weight ≥25 kg	Two NRTIs plus DTG ^e	Yes
		Two NRTIs plus EVG/c ^f	Yes
Adolescents Aged ≥12 Years with SMRs of 1–3	Weight ≥25 kg	Two NRTIs plus BIC ^g	Yes
Adolescents Aged ≥12 Years with SMRs of 4 or 5	Refer to the Adult and Adolescent Antiretroviral Guidelines		Yes
Alternative Regimens			
Age	Regimens		FDC Available (see Appendix A, Table 1)
Children Aged ≥14 Days to <3 Years	Two NRTIs plus NVP ^h		No
Children Aged ≥3 Months to <3 Years	Two NRTIs plus ATV/r		No
Children Aged ≥3 Years	Weight ≥20 kg to <25 kg	Two NRTIs plus DTG ^e	No
Children Aged ≥3 Years	Weight ≥25 kg	Two NRTIs plus ATV/r	No
		Two NRTIs plus DRV/r ^d	No
		Two NRTIs plus RAL ^c	No
Children Aged ≥3 Years	Two NRTIs plus EFV ⁱ		No ^j
	Two NRTIs plus LPV/r		No
Children Aged ≥6 Years to <12 Years	Weight ≥25 kg	Two NRTIs plus BIC ^g	Yes
Adolescents Aged ≥12 Years with SMRs of 1–3	Weight ≥35 kg	Two NRTIs plus RPV ^k	Yes
		Two NRTIs plus ATV/c	No ^j
	Weight ≥40 kg	Two NRTIs plus DRV/c ^l	Yes
Adolescents Aged ≥12 Years with SMRs of 4 or 5	Refer to the Adult and Adolescent Antiretroviral Guidelines		Yes
Preferred Dual-NRTI Backbone Options for Use in Combination with Other Drugs			
Age	Dual-NRTI Backbone Options		FDC Available
Children, Birth to Age <3 Months	ZDV plus (3TC or FTC) ^m		No ^j

Table 7. Antiretroviral Regimens Recommended for Initial Therapy for HIV Infection in Children,
continued

Preferred Dual-NRTI Backbone Options for Use in Combination with Other Drugs, continued		
Age	Dual-NRTI Backbone Options	FDC Available
Children Aged ≥3 Months to <6 Years	ABC plus (3TC ⁿ or FTC)	Yes
	ZDV plus (3TC ^m or FTC)	Yes
Children and Adolescents Aged ≥6 Years with SMRs of 1–3	ABC plus (3TC ⁿ or FTC)	Yes
	Weighing ≥25 kg and receiving a regimen that contains an INSTI or an NNRTI	Yes
Adolescents Aged ≥12 Years with SMRs of 4 or 5	Refer to the Adult and Adolescent Antiretroviral Guidelines	Yes
Alternative Dual-NRTI Backbone Options for Use in Combination with Other Drugs		
Age	Dual-NRTI Backbone Options	FDC Available
Children Aged ≥3 Months	ZDV plus ABC	No
Children Aged ≥2 Years to 12 Years	TDF plus (3TC or FTC) ^p	Yes
Children and Adolescents Aged ≥6 Years and SMRs of 1–3	ZDV plus (3TC or FTC) ^m	Yes

^a If treatment is scheduled to begin before a patient is aged 14 days, NVP or RAL are *Preferred* agents because they are the only options with dosing information available for this age group. While many pediatric experts favor initiating ART as soon as possible after birth in order to limit the establishment of viral reservoirs, available clinical trial data does not suggest that initiating treatment within the first 14 days of life leads to better clinical outcomes than initiating treatment after 14 days of age. Clinicians should consult an expert in pediatric HIV infection before initiating treatment in infants aged <14 days. Additional considerations regarding the use of NVP or RAL in infants aged <14 days can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#). Switching from NVP to LPV/r should be considered when the infant is aged ≥14 days with a postmenstrual age of 42 weeks (the span of time between the first day of the mother's last menstrual period and birth, plus the time elapsed after birth); LPV/r has produced better clinical outcomes in studies of children aged <3 years than NVP. Data are limited on the clinical outcomes of using RAL in infants and children aged <2 years.

^b In general, LPV/r **should not be administered** to neonates before a postmenstrual age of 42 weeks and postnatal age ≥14 days (see the [Lopinavir/Ritonavir](#) section in [Appendix A: Pediatric Antiretroviral Drug Information](#)).

^c RAL pills or chewable tablets can be used in children aged ≥2 years. Granules can be administered in infants and children from birth to age 2 years. No dosing information is available for preterm infants or those weighing <2 kg at birth.

^d DRV should only be used in children weighing ≥10 kg. Once-daily DRV should not be used in children aged <12 years or weighing <40 kg. Once-daily DRV should also not be used when any one of the following resistance-associated substitutions are present: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V. DRV/r is recommended as an *Alternative* drug combination for children aged ≥6 years to <12 years and weighing >25 kg, because there are other drugs that can be administered once daily and that are better tolerated. Note that DRV/r can be administered once daily in adolescents aged ≥12 years and weighing ≥40 kg who are not sexually mature (SMR 1–3).

^e DTG is recommended as a *Preferred* agent for children and adolescents aged ≥3 years and weighing ≥25 kg. It is recommended as an *Alternative* agent in children aged ≥3 years and weighing 20 kg to <25 kg. An FDC tablet that contains ABC/DTG/3TC (Triumeq) is available for children weighing ≥25 kg.

^f EVG is currently recommended only as a component of FDC tablets. Tablets that contain EVG/c/FTC/TAF (Genvoya) are recommended as a *Preferred* regimen for children and adolescents weighing ≥25 kg.

^g BIC is available only as part of an FDC tablet that contains BIC/FTC/TAF (Biktarvy); this FDC tablet is recommended as a *Preferred* regimen for adolescents aged ≥12 years and weighing ≥25 kg. It is recommended as an *Alternative* regimen for children aged ≥6 years and weighing ≥25 kg.

^h NVP should not be used in post-pubertal girls with CD4 counts >250/mm³, unless the benefit clearly outweighs the risk. NVP is approved by the FDA for treatment of infants aged ≥15 days.

ⁱ EFV is approved by the FDA for use in children aged ≥3 months and weighing ≥3.5 kg, but **it is not recommended** by the Panel for initial therapy in children aged ≥3 months to 3 years. FDC tablets that contain EFV/FTC/TDF (Atripla) and EFV 600 mg/3TC/TDF (Symfi) are available. See the [Efavirenz](#) section in [Appendix A: Pediatric Antiretroviral Drug Information](#) for information about use of the FDC EFV 400 mg/3TC/TDF (Symfi Lo).

^j FDA-approved FDC tablets are not included in this table when they are not approved for use in the specific patient populations being discussed.

^k RPV should be administered to adolescents aged ≥12 years and weighing ≥35 kg who have initial viral loads ≤100,000 copies/mL. FDC tablets that contain FTC/RPV/TAF (Odefsey) and FTC/RPV/TDF (Complera) are available.

Table 7. Antiretroviral Regimens Recommended for Initial Therapy for HIV Infection in Children,
continued

DRV/c is available as part of an FDC tablet containing DRV/c/FTC/TAF (Symtuza) that has been approved by the FDA for use in children and adolescents weighing ≥ 40 kg.

^m An FDC tablet that contains 3TC/ZDV (Combivir and generic) is available for use in children weighing ≥ 30 kg.

ⁿ An FDC tablet that contains ABC/3TC (Epzicom and generic) is available for use in children weighing ≥ 25 kg.

^o FTC plus TAF is recommended as a *Preferred* combination for children and adolescents weighing ≥ 25 kg; an FDC tablet that contains FTC/TAF (Descovy) is available. FTC/TAF is approved by the FDA for children weighing ≥ 25 kg when used in the single-tablet regimen EVG/c/FTC/TAF or as TAF/FTC in combination with an NNRTI or INSTI. FTC/TAF plus a boosted PI is only recommended for use in children and adolescents weighing ≥ 35 kg.

^p An FDC tablet that contains FTC/TDF (Truvada) is available.

Key: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; **ATV/c = atazanavir/cobicistat**; ATV/r = atazanavir/ritonavir; BIC = bictegravir; CD4 = CD4 T lymphocyte; COBI = cobicistat; DRV = darunavir; **DRV/c = darunavir/cobicistat**; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; **EVG/c = elvitegravir/cobicistat**; FDA = Food and Drug Administration; FDC = fixed-dose combination; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; the Panel = the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children (page 1 of 4)

See [Appendix A: Pediatric Antiretroviral Drug Information](#) and [Table 7. Antiretroviral Regimen Considerations for Initial Therapy Based on Specific Clinical Scenarios](#) in the [Adult and Adolescent Antiretroviral Guidelines](#) for more information.

ARV Class	ARV Agent(s)	Advantages	Disadvantages
INSTIs In Alphabetical Order	All INSTIs	INSTI Class Advantages: <ul style="list-style-type: none"> Few drug-drug interactions Well-tolerated 	INSTI Class Disadvantages: <ul style="list-style-type: none"> Limited data on pediatric dosing or safety
	BIC	Once-daily administration Can give with or without food Available in FDC tablets (see Appendix A, Table 1)	The FDC tablet is not recommended for patients with hepatic impairment or an estimated CrCl < 30 mL/min. The FDC tablet should not be coadministered with rifampin or dofetilide.
	DTG	Once-daily administration Can give with food Available in FDC tablets (see Appendix A, Table 1) Single-agent DTG pills are available in several doses and are small in size.	Drug interactions with EFV, FPV/r, TPV/r, and rifampin, necessitating twice-daily dosing of DTG CNS side effects, particularly sleep disturbances and possible increased risk of NTDs in infants born to women who were receiving DTG at the time of conception
	EVG	Once-daily administration Available in FDC tablets (see Appendix A, Table 1)	Among INSTIs, EVG has the lowest barrier to the development of resistance. If EVG is coadministered with COBI, there is potential for multiple drug interactions because COBI is metabolized by hepatic enzymes (e.g., CYP3A4). COBI inhibits tubular secretion of creatinine, and this may result in increased serum creatinine but normal glomerular clearance.

Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children (page 2 of 4)

ARV Class	ARV Agent(s)	Advantages	Disadvantages
INSTIs In Alphabetical Order, continued	RAL	Can give with food Available in tablet, chewable tablet, and powder formulations Once-daily administration (with RAL HD) can be used for treatment-naïve or virologically suppressed children weighing ≥ 40 kg.	Potential for rare systemic allergic reaction or hepatitis Granule formulation requires a multistep preparation before administration; caregiver must be taught how to properly prepare this formulation.
NNRTIs In Alphabetical Order	All NNRTIs	NNRTI Class Advantages: <ul style="list-style-type: none"> • Long half-life • Lower risk of dyslipidemia and fat maldistribution than PIs • PI-sparing • Lower pill burden than PIs for children taking the solid formulation; easier to use and adhere to than PI-based regimens 	NNRTI Class Disadvantages: <ul style="list-style-type: none"> • A single mutation can confer resistance, with cross-resistance between EFV and NVP. • Rare but serious and potentially life-threatening cases of skin rash, including SJS, and hepatic toxicity. All NNRTIs pose this risk, but the risk is greatest with NVP. • Potential for multiple drug interactions due to metabolism via hepatic enzymes (e.g., CYP3A4)
	EFV	Once-daily administration Available in FDC tablets (see Appendix A, Table 1) Potent ARV activity Can give with food (but avoid high-fat meals) Capsules can be opened and added to food.	Neuropsychiatric AEs (bedtime dosing is recommended to reduce CNS effects) Rash (generally mild) No commercially available liquid formulation Limited data on dosing for children aged <3 years No data on dosing for children aged <3 months
	NVP	Liquid formulation is available. Dosing information for young infants is available. Can give with food Extended-release formulation is available that allows for once-daily dosing in older children.	Reduced virologic efficacy in young infants, regardless of exposure to NVP as part of a peripartum preventive regimen Higher incidence of rash/HSR than other NNRTIs Higher rates of serious hepatic toxicity than EFV Decreased virologic response compared with EFV Twice-daily dosing necessary in children with BSA <0.58 m ² Low barrier to resistance
	RPV	Once-daily dosing Available in FDC tablets (see Appendix A, Table 1)	Should not use in patients with viral loads >100,000 copies/mL Must be taken with a ≥ 500 kcal meal at a consistent time each day; this may affect adherence. Low barrier to resistance
PIs In Alphabetical Order	All PIs	PI Class Advantages: <ul style="list-style-type: none"> • NNRTI-sparing • Clinical, virologic, and immunologic efficacy are well-documented. • Resistance to PIs requires multiple mutations. • When combined with a dual-NRTI backbone, a regimen that contains a PI targets HIV at two steps of viral replication by inhibiting the activity of viral reverse transcriptase and protease enzymes. 	PI Class Disadvantages: <ul style="list-style-type: none"> • Metabolic complications, including dyslipidemia, fat maldistribution, and insulin resistance • Potential for multiple drug interactions because of metabolism via hepatic enzymes (e.g., CYP3A4) • Higher pill burden than NRTI-based or NNRTI-based regimens for patients taking solid formulations • Poor palatability of liquid preparations, which may affect adherence • Most PIs require RTV boosting, resulting in drug interactions that are associated with RTV

Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children (page 3 of 4)

ARV Class	ARV Agent(s)	Advantages	Disadvantages
PIs In Alphabetical Order, continued	Boosted ATV	Once-daily dosing Powder formulation is available. ATV has less effect on TG and total cholesterol levels than other PIs (but RTV boosting may be associated with elevations in these parameters).	No liquid formulation Should be administered with food Indirect hyperbilirubinemia is common, but asymptomatic. Scleral icterus may be distressing to the patient, which may affect adherence. Must be used with caution in patients with pre-existing conduction system defects (can prolong PR interval of ECG). RTV is associated with a large number of drug interactions.
	Boosted DRV	Can be used once daily in children aged ≥ 12 years Liquid formulation is available. DRV requires a boosting agent. Available in FDC tablets (see Appendix A, Table 1)	Pediatric pill burden high with current tablet dose formulations Should be administered with food Must be boosted to achieve adequate plasma concentrations Contains sulfa moiety. The potential for cross-sensitivity between DRV and other drugs in sulfonamide class is unknown. RTV is associated with a large number of drug interactions. Can only be used once daily in the absence of certain PI-associated resistance mutations
	LPV/r	LPV is only available coformulated with RTV in liquid and tablet formulations. Tablets can be given without regard to food, but they may be tolerated better when taken with meal or snack.	Poor palatability of liquid formulation (bitter taste). Liquid formulation should be administered with food. RTV is associated with a large number of drug interactions. Should not be administered to neonates before a postmenstrual age of 42 weeks (the span of time between the first day of the mother's last menstrual period and birth, plus the time elapsed after birth) and a postnatal age ≥ 14 days Must be used with caution in patients with pre-existing conduction system defects (can prolong PR and QT interval of ECG)
Dual-NRTI Backbones In Alphabetical Order	ABC plus (3TC or FTC)	Palatable liquid formulations Can give with food Available in FDC tablets (see Appendix A, Table 1)	Risk of ABC HSR; perform HLA-B*5701 screening before initiating ABC.
	FTC/TAF for children aged ≥ 6 years	Once-daily dosing Small tablet size Lower risk of TFV-associated renal and bone toxicity with TAF than with TDF in adults Available in FDC tablets (see Appendix A, Table 1)	Limited data on the safety and efficacy of this combination in children Increased lipid levels

Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children (page 4 of 4)

ARV Class	ARV Agent(s)	Advantages	Disadvantages
Dual-NRTI Backbones In Alphabetical Order, continued	TDF plus (3TC or FTC) for adolescents with SMRs of 4 or 5	Once-daily dosing for TDF Resistance is slow to develop. Lower risk of mitochondrial toxicity than other NRTIs Can give with food Available as reduced-strength tablets and oral powder for use in younger children Available in FDC tablets (see Appendix A, Table 1)	Limited pediatric experience Potential bone and renal toxicity Appropriate dosing is complicated by numerous drug-drug interactions with other ARV agents, including ddI, LPV/r, ATV, and TPV.
	ZDV plus (3TC or FTC)	Extensive pediatric experience Coformulations of ZDV and 3TC are available (Combivir and generic) for children weighing ≥30 kg. Palatable liquid formulations Can give with food FTC is available as a palatable liquid formulation that can be administered once daily.	Bone marrow suppression and lipoatrophy with ZDV
	ZDV plus ABC	Palatable liquid formulations Can give with food	Risk of ABC HSR; perform HLA-B*5701 screening before initiating ABC. Bone marrow suppression and lipoatrophy with ZDV

Key: 3TC = lamivudine; ABC = abacavir; AE = adverse event; ARV = antiretroviral; ATV = atazanavir; BIC = bictegravir; BSA = body surface area; CNS = central nervous system; COBI = cobicistat; **CrCl = creatinine clearance**; CYP = cytochrome P450; ddI = didanosine; DRV = darunavir; DTG = dolutegravir; ECG = electrocardiogram; EFV = efavirenz; EVG = elvitegravir; FDC = fixed-dose combination; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; HD = high dose; HSR = hypersensitivity reaction; INSTI = integrase strand transfer inhibitor; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NTD = neural tube defect; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SJS = Stevens-Johnson Syndrome; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TFV = tenofovir; TG = triglyceride; TPV = tipranavir; TPV/r = tipranavir/ritonavir; ZDV = zidovudine

References

1. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. *N Engl J Med*. 2012;366(25):2380-2389. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22716976>.
2. Barlow-Mosha L, Angelidou K, Lindsey J, et al. Nevirapine- versus lopinavir/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: long-term follow-up of the IMPAACT P1060 randomized trial. *Clin Infect Dis*. 2016;63(8):1113-1121. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27439527>.
3. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. *JAMA*. 2010;304(10):1082-1090. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20823434>.
4. Murnane PM, Stehlau R, Shiao S, et al. Switching to efavirenz versus remaining on ritonavir-boosted lopinavir in HIV-infected children exposed to nevirapine: long-term outcomes of a randomized trial. *Clin Infect Dis*. 2017;65(3):477-485. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28419200>.
5. Babiker A, Castro nee Green H, Compagnucci A, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an

open-label, randomised Phase 2/3 trial. *Lancet Infect Dis*. 2011;11(4):273-283. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21288774>.

6. Ruel TD, Kakuru A, Ikilezi G, et al. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. *J Acquir Immune Defic Syndr*. 2014;65(5):535-541. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24326597>.
7. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis*. 2013;13(11):927-935. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24074642>.
8. Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. *J Int AIDS Soc*. 2014;17(4 Suppl 3):19490. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25393999>.
9. Viani RM, Alvero C, Fenton T, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. *Pediatr Infect Dis J*. 2015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26244832>.
10. Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. *Antimicrob Agents Chemother*. 2016;60(12):7086-7097. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27645238>.
11. Hassounah SA, Alikhani A, Oliveira M, et al. Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1. *Antimicrob Agents Chemother*. 2017;61(12). Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28923862>.
12. Neogi U, Singh K, Aralaguppe SG, et al. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. *AIDS*. 2018;32(4):469-476. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29239896>.
13. Oliveira M, Ibanescu RI, Anstett K, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. *Retrovirology*. 2018;15(1):56. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30119633>.
14. Gaur A, Cotton M, Rodriguez C, et al. Bictegravir/FTC/TAF single-tablet regimen in adolescents & children: Week 48 results. Presented at: Conference on Retroviruses and Opportunistic Infections. 2019. Seattle, Washington. Available at: <http://www.croiwebcasts.org/p/2019croi/46>
15. Cotton M, Liberty A, Rodriguez CA, et al. Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single-tablet regimen in HIV-1-infected children (6 to < 12 years). Presented at: International AIDS Conference. 2018. Amsterdam, Netherlands. Available at: http://www.natap.org/2018/IAC/IAC_39.htm.
16. Wiznia A, Alvero C, Fenton T, et al. IMPAACT 1093: dolutegravir in 6- to 12-year-old HIV-infected children: 48-week results. Presented at: Conference on Retroviruses and Opportunistic Infections. 2016. Boston, Massachusetts.
17. Viani R, Carmelita A, Fenton T, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV+ children. Presented at: Conference on Retroviruses and Opportunistic Infections. 2014. Boston, MA.
18. Bollen P, Turkova A, Mujuru H, et al. Adult dolutegravir 50 mg film-coated tablets in children living with HIV weighing 20 to < 25 kg. Presented at: Conference on Retroviruses and Opportunistic Infections. 2019. Seattle, Washington.
19. Ruel T, Acosta EP, Singh R, et al. Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSKI349572) dispersible tablets in HIV-infected children aged 4 weeks to <6 years: results from IMPAACT PI093. Presented at: International AIDS Conference. 2018. Amsterdam, Netherlands. Available at: http://www.natap.org/2018/IAC/IAC_44.htm.
20. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. *N Engl J Med*. 2018;379(10):979-981. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30037297>.

21. Zash R, Holmes L, Makhema J, et al. Surveillance for neural tube defects following antiretroviral exposure from conception. Presented at: International AIDS Conference. 2018. Amsterdam, Netherlands. Available at: http://www.natap.org/2018/IAC/IAC_52.htm.
22. Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in botswana. *N Engl J Med*. 2019;381(9):827-840. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31329379>.
23. Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naïve patients: week 96 and week 144 results from the SINGLE randomized clinical trial. *J Acquir Immune Defic Syndr*. 2015;70(5):515-519. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26262777>.
24. Viani RM, Ruel T, Alvero C, et al. Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: results of the IMPAACT P1093 Study. *J Pediatric Infect Dis Soc*. 2019. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30951600>.
25. Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. *J Acquir Immune Defic Syndr*. 2014;65(3):e118-120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24256630>.
26. Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs. ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. *J Acquir Immune Defic Syndr*. 2014;65(3):e121-124. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24346640>.
27. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials. *Lancet*. 2015;385(9987):2606-2615. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25890673>.
28. Gaur A, Fourle J, et al. Pharmacokinetics, efficacy and safety of an integrase inhibitor STR in HIV-infected adolescents. Presented at: Conference on Retroviruses and Opportunistic Infections. 2014. Boston, Massachusetts.
29. Gaur AH, Kizito H, Prasitsuebsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naïve, HIV-infected adolescents: a single-arm, open-label trial. *Lancet HIV*. 2016;3(12):e561-e568 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27765666>.
30. Gaur A, Natukunda E, Kosalaraksa P, et al. Pharmacokinetics, safety & efficacy of E/C/F/TAF in HIV-infected children (6-12 yrs). Presented at: Conference on Retroviruses and Opportunistic Infections. 2017. Seattle, Washington.
31. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. *Lancet*. 2009;374(9692):796-806. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19647866>.
32. DeJesus E, Rockstroh JK, Lennox JL, et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. *HIV Clin Trials*. 2012;13(4):228-232. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22849964>.
33. Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK. *J Acquir Immune Defic Syndr*. 2013;63(1):77-85. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23412015>.
34. Lennox JL, Landovitz RJ, Ribaud HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: a randomized, controlled equivalence trial. *Ann Intern Med*. 2014;161(7):461-471. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25285539>.
35. Briz V, Leon-Leal JA, Palladino C, et al. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. *Pediatr Infect Dis J*. 2012;31(3):273-277. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22330165>.
36. Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-

infected children aged 2 through 18 years. *Clin Infect Dis*. 2014;58(3):413-422. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24145879>.

37. Nachman S, Alvero C, Acosta EP, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. *J Pediatric Infect Dis Soc*. 2015;4(4):e76-83. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26582887>.
38. Nachman S, Alvero C, Teppler H, et al. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a Phase 1/2 open label, non-randomised, multicentre trial. *Lancet HIV*. 2018;5(12):e715-e722. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30527329>.
39. Clarke D, Acosta A, Cababasay MP, et al. Raltegravir pharmacokinetics and safety in HIV-1 exposed neonates: dose-finding study. Presented at: Conference on Retroviruses and Opportunistic Infections. 2017. Seattle, Washington.
40. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. *N Engl J Med*. 1999;341(25):1874-1881. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10601506>.
41. Teglas JP, Quartier P, Treluyer JM, Burgard M, Gregoire V, Blanche S. Tolerance of efavirenz in children. *AIDS*. 2001;15(2):241-243. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11216933>.
42. Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. *HIV Clin Trials*. 2002;3(3):186-194. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12032877>.
43. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. *J Acquir Immune Defic Syndr*. 2004;36(5):1011-1019. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15247553>.
44. Torti C, Maggiolo F, Patroni A, et al. Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER cohort. *J Antimicrob Chemother*. 2005;56(1):190-195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15917286>.
45. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med*. 2008;358(20):2095-2106. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18480202>.
46. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. *J Infect Dis*. 2010;201(6):803-813. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20151839>.
47. Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the Phase 3 double-blind randomized ECHO and THRIVE Trials. *J Acquir Immune Defic Syndr*. 2012;60(1):33-42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22343174>.
48. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3 trial, analysis of results after 48 weeks. *Lancet*. 2012;379(9835):2439-2448. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22748591>.
49. Spector SA, Hsia K, Yong FH, et al. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children. *J Infect Dis*. 2000;182(6):1769-1773. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11069252>.
50. Starr SE, Fletcher CV, Spector SA, et al. Efavirenz liquid formulation in human immunodeficiency virus-infected children. *Pediatr Infect Dis J*. 2002;21(7):659-663. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12237599>.
51. Fraaij PL, Neubert J, Bergshoeff AS, et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. *Antivir Ther*. 2004;9(2):297-299. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15134193>.

52. Funk MB, Notheis G, Schuster T, et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. *Eur J Med Res*. 2005;10(12):503-508. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16356864>.
53. McKinney RE Jr, Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naïve children and adolescents: Pediatric AIDS clinical trials group protocol P1021. *Pediatrics*. 2007;120(2):e416-423. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17646352>.
54. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. *Clin Infect Dis*. 2005;41(11):1648-1653. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16267739>.
55. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. *AIDS*. 2001;15(1):71-75. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11192870>.
56. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. *AIDS*. 2002;16(9):1201-1215. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12045485>.
57. Zugar A. Studies disagree on frequency of late CNS side effects from efavirenz. *AIDS Clin Care*. 2006;4(1).
58. Kaul S, Ji P, Lu M, Nguyen KL, Shangguan T, Grasela D. Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. *Am J Health Syst Pharm*. 2010;67(3):217-222. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20101064>.
59. Bardsley-Elliott A, Perry CM. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. *Paediatr Drugs*. 2000;2(5):373-407. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11022799>.
60. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. *N Engl J Med*. 1997;336(19):1343-1349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9134874>.
61. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. *N Engl J Med*. 2004;350(24):2471-2480. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15190139>.
62. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. *AIDS*. 2003;17(11):1639-1647. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12853746>.
63. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. *N Engl J Med*. 2010;363(16):1510-1520. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20942667>.
64. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. *Lancet*. 2004;363(9417):1253-1263. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15094269>.
65. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naïve HIV-1 patients: the ARTEN Trial. *Antivir Ther*. 2011;16(3):339-348. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21555816>.
66. Kanya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2007;46(2):187-193. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17693883>.
67. Lowenthal ED, Ellenberg JH, Machine E, et al. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. *JAMA*. 2013;309(17):1803-1809. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23632724>.
68. Kekitiinwa A, Spyer M, et al. Virologic response to efavirenz vs. nevirapine-containing ART in the ARROW trial. Presented at: Conference on Retroviruses and Opportunistic Infections. 2014. Boston, Massachusetts.
69. Baylor M, Ayime O, Truffa M, et al. Hepatotoxicity associated with nevirapine use in HIV-infected children. Presented at: Conference on Retroviruses and Opportunistic Infections. 2005. Boston, Massachusetts. Available at: <http://www>.

70. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. *J Int AIDS Soc*. 2010;13:31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20691049>.
71. Kea C, Puthanakit T, et al. Incidence and risk factors for nevirapine related toxicities among HIV-infected Asian children randomized to starting ART at different CD4%. Abstract MOPE240. Presented at: International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. 2011. Rome, Italy.
72. Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? *Lancet Infect Dis*. 2007;7(11):733-738. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17961859>.
73. Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. *Cochrane Database Syst Rev*. 2016;12:CD004246. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27943261>.
74. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a Phase 3, randomised, non-inferiority trial. *Lancet*. 2011;378(9787):229-237. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21763935>.
75. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naïve, HIV-1 patients in two Phase III randomized trials. *AIDS*. 2013;27(6):939-950. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23211772>.
76. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a Phase 3 randomised double-blind active-controlled trial. *Lancet*. 2011;378(9787):238-246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21763936>.
77. Lombaard J, Bunupuradah T, Flynn PM, et al. Rilpivirine as a treatment for HIV-infected antiretroviral-naïve adolescents: Week 48 safety, efficacy, virology and pharmacokinetics. *Pediatr Infect Dis J*. 2016;35(11):1215-1221. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27294305>.
78. Lombaard J, Bunupuradah T, et al. Safety and efficacy of a rilpivirine-based regimen in HIV-infected treatment-naïve adolescents: Week 24 primary analysis of the PAINT Phase II trial. Presented at: International Workshop on HIV Pediatrics. 2014. Melbourne, Australia.
79. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (A1424-097) 48-week results. *Clin Infect Dis*. 2007;44(11):1484-1492. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17479947>.
80. Cotton MF, Liberty A, Torres-Escobar I, et al. Safety and efficacy of atazanavir powder and ritonavir in HIV-1-infected infants and children from 3 months to <11 years of age: the PRINCE-2 study. *Pediatr Infect Dis J*. 2018;37(6):e149-e156. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29206747>.
81. Sevinsky H, Zaru L, Wang R, et al. Pharmacokinetics and pharmacodynamics of atazanavir in HIV-1-infected children treated with atazanavir powder and ritonavir: combined analysis of the PRINCE-1 and -2 Studies. *Pediatr Infect Dis J*. 2018;37(6):e157-e165. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29206748>.
82. Malan DR, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naïve patients. *J Acquir Immune Defic Syndr*. 2008;47(2):161-167. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17971713>.
83. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. *J Acquir Immune Defic Syndr*. 2010;53(3):323-332. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20032785>.
84. Kiser JJ, Fletcher CV, Flynn PM, et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil

fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. *Antimicrob Agents Chemother*. 2008;52(2):631-637. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18025112>.

85. Kiser JJ, Rutstein RM, Samson P, et al. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. *AIDS*. 2011;25(12):1489-1496. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21610486>.
86. Rutstein RM, Samson P, Fenton T, et al. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the pediatric AIDS clinical trials group protocol 1020A. *Pediatr Infect Dis J*. 2015;34:162-167. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25232777>.
87. Strehlau R, Donati AP, Arce PM, et al. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged \geq 3 months to $<$ 6 years. *J Int AIDS Soc*. 2015;18:19467. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26066346>.
88. McFarland EJ, Heresi GP, Batra J, et al. Pharmacokinetics, safety, and efficacy of ATV or DRV with COBI in adolescents. Presented at: Conference on Retroviruses and Opportunistic Infections. 2017. Seattle, Washington.
89. Kakuda TN, Brochot A, van de Casteele T, Opsomer M, Tomaka F. Establishing darunavir dosing recommendations in treatment-naïve and treatment-experienced pediatric patients. Presented at: Clinical Pharmacology Workshop on HIV. 2013. Amsterdam, Netherlands. Available at: http://www.natap.org/2013/Pharm/Pharm_19.htm.
90. King J, Hazra R, et al. Pharmacokinetics of darunavir 800 mg with ritonavir 100 mg once daily in HIV+ adolescents and young adults. Presented at: Conference on Retroviruses and Opportunistic Infections. 2013. Atlanta, Georgia.
91. Food and Drug Administration. Tybost supplemental approval. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/203094Orig1s013ltr.pdf
92. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. *AIDS*. 2008;22(12):1389-1397. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18614861>.
93. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis. *AIDS*. 2009;23(13):1679-1688. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19487905>.
94. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label Phase 3b study. *Lancet*. 2014;383(9936):2222-2231. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24698485>.
95. Flynn P, Komar S, Blanche S, et al. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a Phase 2 open-label trial (DIONE). *Pediatr Infect Dis J*. 2014;33(9):940-945. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25361024>.
96. Blanche S, Bologna R, Cahn P, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. *AIDS*. 2009;23(15):2005-2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19724191>.
97. Violari A, Bologna R, Kumarasamy N, et al. Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial. *Pediatr Infect Dis J*. 2015;34(5):e132-137. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25719453>.
98. Mascolini M. Darunavir dosing determined for naïve and experienced children and youth. Presented at: International Workshop on Clinical Pharmacology of HIV Therapy. 2013. Amsterdam, Netherlands.
99. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naïve subjects through 48 weeks. *J Acquir Immune Defic Syndr*. 2009;50(5):474-481. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19225400>.
100. van der Flier M, Verweel G, van der Knaap LC, et al. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily. *Antivir Ther*. 2008;13(8):1087-1090. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19195335>.

101. la Porte C, van Heeswijk R, Mitchell CD, Zhang G, Parker J, Rongkavilit C. Pharmacokinetics and tolerability of once-versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children. *Antivir Ther.* 2009;14(4):603-606. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19578247>.
102. Lyall H. Final results of Koncert: A randomized noninferiority trial of QD vs BD LPV/r dosing in children. Presented at: Conference on Retroviruses and Opportunistic Infections. 2014. Boston, Massachusetts.
103. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. *Lancet.* 2006;368(9534):476-482. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16890834>.
104. Pulido F, Estrada V, Baril JG, et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. *HIV Clin Trials.* 2009;10(2):76-87. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19487177>.
105. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. *J Acquir Immune Defic Syndr.* 2009;50(4):367-374. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19214123>.
106. Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. *HIV Med.* 2013;14(1):49-59. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23088336>.
107. Paediatric European Network for Treatment of AIDS. Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children. *AIDS.* 2015;29(18):2447-2457. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26558544>.
108. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. *Lancet.* 2002;359(9308):733-740. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11888583>.
109. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. *Pediatrics.* 2006;118(3):e711-718. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16923923>.
110. Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Vigano A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. *J Acquir Immune Defic Syndr.* 2005;40(4):448-450. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16280700>.
111. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. *Antimicrob Agents Chemother.* 2004;48(1):124-129. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14693529>.
112. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. *Pediatrics.* 2005;116(6):e846-854. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16291735>.
113. Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. *Antivir Ther.* 2006;11(3):377-384. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16759055>.
114. Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. *AIDS.* 2004;18(12):1691-1696. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15280780>.
115. Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. *AIDS.* 2007;21(8):947-955. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17457088>.
116. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. *N Engl J Med.* 2009;361(23):2230-2240. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19952143>.

117. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. *AIDS*. 2009;23(12):1547-1556. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19542866>.
118. Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. *Cochrane Database Syst Rev*. 2010(10):CD008740. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20927777>.
119. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naïve, HIV-1-infected adults: 48-week results from the ASSERT study. *J Acquir Immune Defic Syndr*. 2010;55(1):49-57. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20431394>.
120. Mulenga V, Musiime V, Kekitiinwa A, et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. *Lancet Infect Dis*. 2016;16(2):169-179. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26481928>.
121. Technau KG, Lazarus E, Kuhn L, et al. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. *Pediatr Infect Dis J*. 2013;32(8):851-855. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23860481>.
122. Technau KG, Schomaker M, Kuhn L, et al. Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis. *Pediatr Infect Dis J*. 2014;33(6):617-622. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24378944>.
123. Bergshoeff A, Burger D, Verweij C, et al. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). *Antivir Ther*. 2005;10(2):239-246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15865218>.
124. LePrevost M, Green H, Flynn J, et al. Adherence and acceptability of once daily lamivudine and abacavir in human immunodeficiency virus type-1 infected children. *Pediatr Infect Dis J*. 2006;25(6):533-537. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16732152>.
125. Paediatric European Network for Treatment of AIDS. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. *Antivir Ther*. 2010;15(3):297-305. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20516550>.
126. Musiime V, Kendall L, Bakeera-Kitaka S, et al. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. *Antivir Ther*. 2010;15(8):1115-1124. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21149918>.
127. Kizito H, Gaur A, Prasitsuebsai W, et al. Week-24 data from a Phase 3 clinical trial of E/C/F/TAF in HIV-infected adolescents. Presented at: Conference on Retroviruses and Opportunistic Infections. 2015. Seattle, Washington.
128. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. *JAMA*. 2004;292(2):191-201. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15249568>.
129. Vigano A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. *Clin Drug Investig*. 2011;31(6):407-415. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21528939>.
130. Giacomet V, Maruca K, Ambrosi A, Zuccotti GV, Mora S. A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate. *Int J Antimicrob Agents*. 2017;50(3):365-370. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28689877>.
131. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. *N Engl J Med*. 2006;354(3):251-260. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16421366>.
132. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with

zidovudine/lamivudine and efavirenz in treatment-naïve patients: 144-week analysis. *J Acquir Immune Defic Syndr*. 2008;47(1):74-78. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17971715>.

133. Papaleo A, Warszawski J, Salomon R, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. *Pediatr Infect Dis J*. 2007;26(10):949-951. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17901802>.
134. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. *Pediatr Infect Dis J*. 2009;28(3):204-209. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19209091>.
135. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. *Pediatr Infect Dis J*. 2009;28(7):619-625. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19561425>.
136. Pontrelli G, Cotugno N, Amodio D, et al. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. *BMC Infect Dis*. 2012;12:18. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22269183>.
137. Van Dyke RB, Wang L, Williams PL, Pediatric AIDS Clinical Trials Group 219C Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. *J Infect Dis*. 2008;198(11):1599-1608. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19000014>.
138. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipodystrophy. *AIDS*. 2006;20(16):2043-2050. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17053350>.
139. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipodystrophy: a randomized trial. *JAMA*. 2002;288(2):207-215. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12095385>.